|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1994
|
|
gptkbp:ATCCode
|
A10BA02
|
|
gptkbp:bioavailability
|
50-60%
|
|
gptkbp:brand
|
gptkb:Riomet
gptkb:Fortamet
gptkb:Glucophage
gptkb:Glumetza
|
|
gptkbp:CASNumber
|
657-24-9
|
|
gptkbp:category
|
antidiabetic agent
biguanide
hypoglycemic agent
|
|
gptkbp:contraindication
|
metabolic acidosis
renal impairment
hypersensitivity to metformin
|
|
gptkbp:discoveredBy
|
gptkb:Jean_Sterne
|
|
gptkbp:discoveredIn
|
1957
|
|
gptkbp:drugClass
|
biguanide
|
|
gptkbp:drugInteraction
|
gptkb:beer
cimetidine
iodinated contrast agents
|
|
gptkbp:eliminationHalfLife
|
4-8.7 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:form
|
500 mg
C4H11N5
1000 mg
850 mg
|
|
gptkbp:foundIn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB00490
|
|
gptkbp:indication
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:isGeneric
|
yes
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:maximumDailyDose
|
2550 mg
|
|
gptkbp:mechanismOfAction
|
improves insulin sensitivity
decreases hepatic glucose production
decreases intestinal absorption of glucose
|
|
gptkbp:metabolism
|
not metabolized
|
|
gptkbp:molecularWeight
|
129.164
|
|
gptkbp:name
|
gptkb:Metformin
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
negligible
|
|
gptkbp:PubChem_CID
|
gptkb:DB00490
gptkb:CHEMBL1431
4091
|
|
gptkbp:riskOfLacticAcidosis
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
gastrointestinal upset
lactic acidosis
|
|
gptkbp:synonym
|
1,1-dimethylbiguanide
dimethylbiguanide
|
|
gptkbp:UNII
|
9100L32L2N
|
|
gptkbp:bfsParent
|
gptkb:buspirone
|
|
gptkbp:bfsLayer
|
7
|